Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for Legend Biotech in a ...

AstraZeneca Plc agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion in a deal that will see the British ...

The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...

AIIMS in New Delhi is experiencing severe staff shortages, with hundreds of vacant posts for doctors and faculty members. A ...

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV ...

Celex Oncology's first attendance at Bio-Europe Spring 2025 follows their recent win at the 2024 EIT Health Catapult ...

This oversubscribed Series A funding round was led by General Catalyst with additional investment from new investors, British ...

COAST REGION: TANZANIA is set to become a key player in Africa’s fight against malaria through a major investment in an ...

The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...